Abstract
Coronavirus disease 2019 (COVID-19) is a contagious viral infection caused by coronavirus 2 (SARS-CoV-2) that causes severe acute respiratory syndrome. It has ravaged several countries and burdened many healthcare systems. As the process of authorizing a novel treatment for human use is extensive and involves multiple phases to obtain safety information and identify potential concerns. Therefore, the fastest and easiest choice was to use United States Food and Drug Administration (US FDA)-approved drugs such as favipiravir and hydroxychloroquine. For the simultaneous estimation of both medications, a simple synchronous spectrofluorimetric approach was established in which both drugs were measured at 372 and 323 nm, respectively in the presence of each other without interference at Δλ 60 nm. The effect of various experimental conditions on synchronous fluorescence intensities were thoroughly investigated and optimized. The maximum synchronous fluorescence intensities were obtained at pH 5.4 using acetate buffer (0.2 M, 0.5 ml) and ethanol as a diluent. Excellent linearity ranges were obtained using 1.0-18.0 ng/ml and 10.0-120.0 ng/ml for favipiravir and hydroxychloroquine, respectively. The approach exhibited high sensitivity with detection limits down to 0.25 ng/ml and 1.52 ng/ml and quantitation limits down to 0.77 ng/ml and 4.62 ng/ml, respectively. Spiking human plasma samples with the studied drugs yielded high % recoveries, allowing a significant bioanalytical application. Moreover, the method was validated according to International Conference on Harmonization guidelines and further applied to commercial pharmaceutical preparations with good results.
Keywords: COVID-19; biological fluids; favipiravir; hydroxychloroquine; synchronous fluorimetry.
【저자키워드】 COVID-19, Hydroxychloroquine, Favipiravir, biological fluids, synchronous fluorimetry., 【초록키워드】 Treatment, coronavirus disease, SARS-CoV-2, viral infection, Coronavirus disease 2019, coronavirus, Hydroxychloroquine, Favipiravir, drug, medications, coronavirus 2, Ethanol, Severe acute respiratory syndrome, sensitivity, United States, harmonization, synchronous, information, pharmaceutical preparations, food, Acetate, Detection limit, biological fluids, Interference, Healthcare systems, Pharmaceutical Preparation, acute respiratory syndrome, Drug administration, limits, quantitation, contagious, buffer, United States Food and Drug Administration, International Conference, approach, country, limit, human plasma samples, fluorescence intensity, diluent, identify, caused, United State, investigated, applied, exhibited, condition, cause, were measured, human plasma sample, 【제목키워드】 Treatment, Hydroxychloroquine, Favipiravir, synchronous, Analysis, FDA-approved drug, biological fluid,